At the European Association for the Study of Diabetes (EASD) Annual Meeting 2026, three studies expanded the understanding and management of diabetic peripheral neuropathy (DPN), spanning clinical associations, early risk prediction, and dietary intervention.
Article Key Points
- T2D men (n=247): ED prevalence 64.8%; peripheral neuropathy the strongest determinant of sexual dysfunction
- Mean great toe vibration perception threshold (VPT) was most strongly correlated with ED severity (r=-0.410, p<0.001)
- 3P cohort (n=229, 9-yr): POCD predicted incident DPN (RR 9.6-10.8), DFU, and mortality with high specificity
- Either-abnormal POCD: 81% sensitivity, 64% specificity for incident DPN; tuning fork alone gave moderate performance
- db/db mice: ADF and 5:2 diets improved DSPN; effects abolished by antibiotics and restored by fecal transplant
- Evidence status: conference abstracts; full results have not yet been peer-reviewed
DPN as an Independent Determinant of Multi-Domain Sexual Dysfunction in T2D Men
Study design: Observational cross-sectional study of 247 men with T2D (mean age 63.3 ± 11.3 years; diabetes duration 15.3 ± 10.7 years; HbA1c 7.0% ± 1.1%). Sexual function was assessed with the International Index of Erectile Function (IIEF-15); sexual distress with the Sexual Distress Scale (SDS). Peripheral neuropathy was evaluated through clinical scores, vibration perception threshold (VPT), and nerve conduction studies. Spearman correlation and multivariable linear regression were used.
Results: Erectile dysfunction (ED) prevalence was 64.8%; 24.3% of patients reported clinically meaningful sexual distress. Peripheral neuropathy prevalence was 47.8% and showed the strongest association with sexual dysfunction, correlating with lower total IIEF scores (rho=-0.330, p<0.001) and erectile function (rho=-0.375, p<0.001), and with desire, orgasmic function, and satisfaction domains (all p<=0.008). Neuropathy was also associated with higher sexual distress (rho=0.254, p<0.001).
Among neurophysiological parameters, peroneal and sural nerve conduction velocities correlated positively with IIEF domains; right peroneal nerve conduction velocity correlated with erectile function at r=0.261 (p<0.001). Mean great toe VPT showed the strongest correlation with dysfunction (total IIEF: r=-0.375, p<0.001; erectile function: r=-0.410, p<0.001). Nephropathy showed a weaker association, and retinopathy did not correlate significantly with sexual function.
The authors noted that peripheral neuropathy is the main determinant of multi-domain sexual dysfunction in T2D men, independently affecting erectile function, desire, orgasm, and sexual distress, and that objective neurophysiological damage correlates with severity, supporting a neurogenic contribution to diabetic ED and pointing to the value of early neuropathy-oriented evaluation.
POCD Stratification Predicts Incident DPN, DFU, and Mortality in the 3P Study
Study design: Prospective study that consecutively enrolled 229 patients with diabetes (92.6% T2D). Baseline assessment used the Toronto Clinical Neuropathy Score (TCNS), 10 g monofilament, 128 Hz tuning fork, and point-of-care devices (POCD). Of those enrolled, 167 patients without clinical DPN were followed for 9 years. DPNCheck (handheld sural nerve conduction/amplitude) and SUDOSCAN (sudomotor function) were compared with 128 Hz tuning fork for predicting incident DPN, DFU, and all-cause mortality. Adjusted Cox or logistic regression estimated relative risk (RR) and 95% confidence interval (CI), sensitivity, and specificity.
Results: At baseline, POCD detected a DPN prevalence of 61.9%, far higher than 10 g monofilament (14.4%). At 9-year follow-up, 37 of the 167 DPN-free patients (22%) had died and 18 (11%) had developed a DFU. For incident DPN, both-abnormal POCD yielded RR 10.8 (95% CI 2.4-48.4; sensitivity 46%, specificity 95%); either-abnormal yielded RR 9.6 (95% CI 2.3-39.4; sensitivity 81%, specificity 64%). For DFU, both-abnormal gave RR 2.3 (95% CI 1.1-10.0; sensitivity 33%, specificity 79%); either-abnormal gave RR 2.3 (95% CI 1.1-10.0; sensitivity 78%, specificity 48%). For mortality, both-abnormal gave RR 1.4 (95% CI 0.6-3.2; sensitivity 41%, specificity 82%); either-abnormal gave RR 2.5 (95% CI 0.9-7.0; sensitivity 76%, specificity 51%).
Tuning fork vibration predicted incident DPN (RR 4.6, 95% CI 1.4-15.4; sensitivity 62%, specificity 74%), DFU (RR 1.7, 95% CI 0.6-5.0; sensitivity 67%, specificity 55%), and mortality (RR 1.7, 95% CI 0.7-4.1; sensitivity 67%, specificity 68%). Only 2 of 167 patients showed abnormal 10 g monofilament.
The authors noted that both-abnormal POCD provided high negative predictive value for incident DPN, DFU, and mortality, while either-abnormal POCD improved sensitivity. Bedside vibration testing, when performed properly, may serve as a simple, inexpensive first-line tool with reasonable sensitivity for early risk detection. A staged vibration-then-POCD strategy may offer a robust clinical pathway for early DPN identification and clinically important outcomes.
Intermittent Fasting via Gut Microbiota Improves DSPN: An Animal Study
Study design: Animal experiment using db/db mice randomized to ad libitum feeding, alternate-day fasting (ADF), or 5:2 diet, with peripheral nerve function assessed. An antibiotic cocktail was used to deplete gut microbiota, and pseudo-germ-free mice receiving fecal microbiota transplantation (FMT) were used to test causality.
Results: Both ADF and 5:2 diets improved peripheral neuropathy, enhanced intestinal barrier function, reduced inflammatory cytokines, and altered gut microbiota. In ADF mice, Lactobacillus murinus and Lachnospiraceae were enriched, while Muribaculaceae and Bacteroides acidifaciens decreased. The 5:2 diet increased Lachnospiraceae and Mucispirillum and decreased Muribaculaceae and Alloprevotella. ADF increased beneficial metabolites such as N-acetylhistamine, asparagine, and butyrate, and decreased harmful N-acetylputrescine and phenylacetylglycine. The 5:2 diet similarly increased N-acetylhistamine and decreased phenylacetylglycine.
Antibiotic-induced depletion of gut microbiota abolished the neuroprotective effects of ADF and 5:2 diets. However, pseudo-germ-free db/db mice receiving FMT from ADF- or 5:2-treated donors showed improved peripheral nerve function and reduced inflammatory cytokines. FMT also reduced N-acetylputrescine and phenylacetylglycine and helped restore colonic epithelial barrier integrity.
The authors noted that the animal study showed ADF and 5:2 diets alleviated DSPN, possibly by modulating gut microbiota, altering gut metabolites, lowering inflammatory cytokines, and restoring intestinal barrier function; the two regimens produced comparable effects, with human validation still pending.
Conclusion
The three studies broaden DPN management from clinical associations to early prediction and dietary intervention. DPN emerged as the main determinant of multi-domain sexual dysfunction in T2D men, supporting routine neuropathy-oriented sexual assessment. The 3P study showed that POCD stratification, after a simple vibration first-line test, can predict incident DPN, DFU, and mortality with high specificity. Animal data suggested ADF and 5:2 diets may improve DSPN through gut microbiota modulation, providing mechanistic leads for dietary intervention that require human validation.